KHK 6640

Drug Profile

KHK 6640

Alternative Names: KHK-6640

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Immunas Pharma
  • Developer Kyowa Hakko Kirin
  • Class Monoclonal antibodies; Nootropics
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 27 Mar 2017 Kyowa Hakko Kirin plans a phase-I clinical trial in Alzheimer's disease (In adults, In the elderly) in Japan (IV) (JapicCTI-173541)
  • 01 Sep 2016 Kyowa Hakko Kirin completes a phase-I clinical trial in Alzheimer's disease in Japan (Parenteral) (NCT02377713)
  • 04 Apr 2016 Phase-I clinical trials in Alzheimer's disease in Serbia & Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top